Search | Clinical Trials Finder

Conditions: Obesity, Overweight, Type 2 Diabetes Mellitus
Interventions: Maridebart Cafraglutide, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 29
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more

Conditions: Obesity
Interventions: Qsymia, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lakewood, Colorado

Conditions: Overweight, Obesity
Interventions: UBT251, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Cypress, California • Overland Park, Kansas

Conditions: Obesity & Overweight
Interventions: CX11, Placebo; Drug · Other
Lead sponsor: Corxel Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: Obesity, Overweight
Interventions: Tirzepatide, Semaglutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 30
States / cities: Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 24 more

Conditions: Obesity
Interventions: NNC0519-0130 B, NNC0519-0130 C; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Alcohol Use Disorder (AUD)
Interventions: Pemvidutide, Placebo; Drug · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 9 more

Conditions: Psoriasis, Overweight or Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 39
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 35 more

Conditions: Obesity, Overweight
Interventions: Ribupatide, Placebo; Drug
Lead sponsor: Kailera; Industry
Eligibility: 18 Years and older
Enrollment: 2,340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 24
States / cities: Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 21 more

Conditions: Obesity
Interventions: S-2367 Placebo, S-2367 800 mg, S-2367 1600 mg, Reduced Calorie Diet; Drug · Other
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 724 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 38
States / cities: Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 35 more

Conditions: Cholesterol, Elevated, Overweight or Obesity
Interventions: RS4 bar, Control bar; Dietary Supplement
Lead sponsor: Kansas State University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Obesity
Interventions: Tradipitant, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 3
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York

Conditions: Obesity, Overweight
Interventions: NNC0174-0833, Placebo (NNC0174-0833); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: Overweight
Interventions: LY3437943, Ethinyl Estradiol, Drospirenone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: South Miami, Florida • San Antonio, Texas

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC0194-0499, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 22 Years to 55 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity or Overweight
Interventions: AZD6234, Placebo comparator; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 23
States / cities: Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 19 more

Conditions: Obesity, Overweight, Type 2 Diabetes
Interventions: LY3549492, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 38
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Greenbrae, California + 33 more

Conditions: Obesity, Overweight
Interventions: Placebo, Enicepatide; Drug
Lead sponsor: Carmot Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 34
States / cities: Birmingham, Alabama • Homewood, Alabama • Mesa, Arizona + 29 more

Conditions: Obesity, Obese, Overweight or Obesity
Interventions: Bimagrumab, Semaglutide, Placebo; Biological · Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Anniston, Alabama • Cullman, Alabama • Hialeah, Florida + 7 more

Conditions: Obesity and Overweight
Interventions: NNC0165-1875, Placebo (NNC0165-1875), Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Male only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Obesity
Interventions: Endoscopic ultrasound shear wave elastography; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Overweight, Obesity
Interventions: NNC6989-0001, Placebo (NNC6989-0001); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 41
States / cities: Birmingham, Alabama • Montgomery, Alabama • Peoria, Arizona + 36 more

Conditions: Body Mass Index Greater Than or Equal to 30, Malignant Breast Neoplasm, Mammoplasty Patient, Obesity
Interventions: Negative Pressure Wound Therapy, Wound Care Management; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine

RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet

Long-term Consumption of Resistant Starch Type-4 (RS4)

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease

A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program

Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery